抗マラリア薬市場：薬剤クラス別、薬剤タイプ別、投与経路別、マラリアタイプ別、流通チャネル別、エンドユーザー別-2025～2030年の世界予測

抗マラリア薬市場は、2023年に16億7,000万米ドルと評価され、2024年には17億6,000万米ドルに達すると予測され、CAGR 5.88％で成長し、2030年には25億米ドルに達すると予測されています。

抗マラリア薬の対象範囲は、主に感染した蚊に刺されることで感染する寄生虫によって引き起こされる病気であるマラリアの予防と治療のための開発、流通、適用です。これらの薬剤の必要性は、特に熱帯・亜熱帯地域でマラリアが蔓延し続け、健康上の大きな課題となっていることからも明らかです。抗マラリア薬は、病気の流行地域だけでなく、そのような地域を訪れる人々のための旅行薬にも応用されます。最終的な使用範囲は、公衆衛生活動、病院、クリニック、薬局での店頭販売などであり、流行地域住民と旅行者の両方に対応します。

市場洞察によると、抗マラリア薬の需要は、世界のマラリア罹患率、国際保健施策、薬剤耐性に関する継続的な研究努力などの要因に影響されています。また、ワクチンや新薬製剤を含む次世代治療法の開発への投資も増加しており、政府のイニシアティブや製薬会社と保健機関との協力関係がその原動力となっています。創薬におけるAIなどの新技術の統合、地方へのアクセス拡大、小児にやさしい製剤の開発などに潜在的な機会があります。しかし、マラリア原虫の薬剤耐性株の出現、薬剤開発の高コスト、規制上のハードルなどの課題から限界が生じる。こうした障害は市場の成長を鈍らせる可能性があり、持続的な研究努力が必要となります。

耐性菌に対処するための併用療法、個別化治療の指針となる迅速診断検査の開発、ワクチン開発にバイオテクノロジーを活用するなどのセグメントでは、技術革新が進展する可能性があります。市場競争は依然として激しいが、研究開発や共同研究への投資を厭わない新規参入企業にはその余地があります。地域の市場力学を理解し、地域のニーズに合わせて製品ラインを多様化することで、市場での存在感を高めることができます。まとめると、抗マラリア薬市場で成長機会をつかむためには、耐性動向への警戒を維持し、技術の進歩を活用し、アクセスの課題に対処することが重要です。

市場力学：急速に進化する抗マラリア薬市場の主要市場洞察を公開

抗マラリア薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響についてより明確に理解することができます。

• 市場促進要因
  • 世界のマラリア罹患率の上昇（特に熱帯・亜熱帯地域）
  • マラリア撲滅プログラムに対する世界保健機関からの支援の増加
• 市場抑制要因
  • 薬剤耐性マラリア株の出現
• 市場機会
  • 抗マラリア薬の普及拡大を目指した政府と製薬企業の協力関係
  • マラリア治療の開発と診断検査の研究開発
• 市場課題
  • 誤った投薬、厳格なコンプライアンス、薬剤の品質低下に関する問題

ポーターのファイブフォース：抗マラリア薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：抗マラリア薬市場における外部からの影響の把握

外部マクロ環境要因は、抗マラリア薬市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：抗マラリア薬市場における競合情勢の把握

抗マラリア薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：抗マラリア薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、抗マラリア薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：抗マラリア薬市場における成功への道筋を描く

抗マラリア薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • マラリアの発生率は世界的に上昇しており、特に熱帯・亜熱帯地域で顕著
    • マラリア撲滅プログラムに対する世界保健機関からの支援の増加
  • 抑制要因
    • 薬剤耐性マラリア株の出現
  • 機会
    • 抗マラリア薬の普及促進に向けた政府と製薬会社の協力
    • マラリアに対する医薬品開発と診断検査の研究開発
  • 課題
    • 投薬量の誤り、厳格な遵守、薬剤の品質の低さに関連する問題
• 市場セグメンテーション分析
  • 薬剤クラス：アルテミシニン化合物の有効性により使用が拡大
  • マラリアタイプ：熱帯マラリア原虫の蔓延が増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 抗マラリア薬市場：薬剤クラス別

• イントロダクション
• 抗葉酸化合物
• アルテミシニン化合物
• アリールアミノアルコール化合物
• エンドペルオキシド
• キノリンメタノール
• テトラサイクリン

第7章 抗マラリア薬市場：薬剤タイプ別

• イントロダクション
• ブランド
• ジェネリック

第8章 抗マラリア薬市場：投与経路別

• イントロダクション
• 静脈内
• 経口

第9章 抗マラリア薬市場：マラリアタイプ別

• イントロダクション
• Plasmodium Falciparum
• Plasmodium Knowlesi
• Plasmodium Malariae
• Plasmodium Ovale
• Plasmodium Vivax

第10章 抗マラリア薬市場：流通チャネル別

• イントロダクション
• 病院薬局
• オンライン薬局
• 小売薬局

第11章 抗マラリア薬市場：エンドユーザー別

• イントロダクション
• 病院
• 専門クリニック

第12章 南北アメリカの抗マラリア薬市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋の抗マラリア薬市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカの抗マラリア薬市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • ケニアの製薬会社がアフリカで初めてマラリア治療としてWHOの承認を取得
  • Fosun PharmaとIFCが提携し、アフリカにおける高品質医薬品へのアクセスを向上
  • Fosun Pharmaが革新的なアルテミシニンベースの抗マラリア薬を開発
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Alkem Laboratories
• Alliance Pharma
• Alvizia Health Care
• Bayer AG
• Cipla Inc.
• Dr. Reddy's Laboratories
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Glenmark Pharmaceuticals
• Hikma Pharmaceuticals PLC
• Ipca Laboratories Ltd.
• Lincoln Pharmaceuticals
• Lupin Limited
• Merck KGaA
• Mylan
• Novartis AG
• Pfizer Inc.
• Sanofi Group
• Strides Pharma Science Limited
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company
• Teva Pharmaceuticals Industries Ltd.
• Zydus Group
• Zydus Lifesciences Ltd.

LIST OF FIGURES

• FIGURE 1. ANTIMALARIAL DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. ANTIMALARIAL DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 21. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. ANTIMALARIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 27. ANTIMALARIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTIMALARIAL DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTIMALARIAL DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ANTIFOLATE COMPOUNDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ COMPOUNDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARYL AMINOALCOHOL COMPOUNDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ENDOPEROXIDES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUINOLINE METHANOLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM FALCIPARUM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM KNOWLESI, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM MALARIAE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM OVALE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PLASMODIUM VIVAX, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 53. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 54. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 55. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 56. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57. CANADA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES ANTIMALARIAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 78. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 79. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 80. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 84. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 85. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 86. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 87. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 88. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. CHINA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 90. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 91. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 92. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 94. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. INDIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 96. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 97. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 98. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 102. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 103. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 104. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 108. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 109. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 110. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 114. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 115. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 116. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 120. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 121. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 132. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 133. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 134. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 138. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 139. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 140. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 144. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 145. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 146. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 157. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 158. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 159. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 163. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 164. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 165. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 169. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 170. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 171. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 175. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 176. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 177. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 181. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 182. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 183. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 187. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 188. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 189. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 193. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 194. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 195. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 196. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 197. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 198. ITALY ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 199. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 200. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 201. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 205. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 206. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 207. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 211. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 212. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 213. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 217. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 218. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 219. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 220. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 221. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 222. POLAND ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 223. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 224. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 225. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 226. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 227. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 228. QATAR ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 229. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 230. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 231. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 235. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 236. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 241. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 242. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 247. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 248. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 249. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 253. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 254. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 255. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 259. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 260. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 261. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 265. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 266. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 267. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 271. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 272. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 277. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 278. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY MALARIA TYPE, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 283. ANTIMALARIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 284. ANTIMALARIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Antimalarial Drugs Market was valued at USD 1.67 billion in 2023, expected to reach USD 1.76 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 2.50 billion by 2030.

The scope of antimalarial drugs encompasses their development, distribution, and application primarily for the prevention and treatment of malaria, a disease caused by parasites transmitted through infected mosquito bites. The necessity for these drugs is underscored by malaria's persistent prevalence, particularly in tropical and subtropical regions, where it poses significant health challenges. Antimalarial drugs find application not only in disease-endemic regions but also in travel medicine for individuals visiting such areas. Ultimately, the end-use scope includes public health initiatives, hospitals, clinics, and over-the-counter availability in pharmacies, catering to both the endemic population and travelers.

Market insights reveal that the demand for antimalarial drugs is influenced by factors such as the global incidence rate of malaria, international health policies, and ongoing research efforts into drug resistance. There's also an increased investment in developing next-generation therapies, including vaccines and novel drug formulations, driven by government initiatives and collaborations between pharmaceutical companies and health organizations. Potential opportunities lie in the integration of new technologies such as AI in drug discovery, expanding access to rural areas, and developing pediatric-friendly formulations. However, limitations arise from challenges such as the emergence of drug-resistant strains of malaria parasites, high costs of drug development, and regulatory hurdles. These impediments may slow market growth and require sustained research efforts.

Innovation can thrive in areas like combination therapies to tackle resistance, development of rapid diagnostic tests that can guide personalized treatment, and leveraging biotechnology for vaccine development. The market remains competitive but offers room for new entrants willing to invest in R&D and collaborations. Understanding regional market dynamics and diversifying product lines to align with specific local needs can enhance market presence. In summary, maintaining vigilance on resistance trends, capitalizing on technological advancements, and addressing access challenges are crucial for seizing growth opportunities in the antimalarial drugs market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antimalarial Drugs Market

The Antimalarial Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidence rates of malaria globally, particularly in tropical and subtropical regions
  • Increasing support from global health organizations for malaria eradication programs
• Market Restraints
  • Emergence of drug-resistant malaria strains
• Market Opportunities
  • Collaborations between governments and pharmaceutical companies for increasing penetration of anti-malaria drugs
  • Research and development in drug development and diagnostic tests for malaria
• Market Challenges
  • Issues related to incorrect dosing, strict compliance, and poor drug quality

Porter's Five Forces: A Strategic Tool for Navigating the Antimalarial Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antimalarial Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antimalarial Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antimalarial Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antimalarial Drugs Market

A detailed market share analysis in the Antimalarial Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antimalarial Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antimalarial Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antimalarial Drugs Market

A strategic analysis of the Antimalarial Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antimalarial Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alkem Laboratories, Alliance Pharma, Alvizia Health Care, Bayer AG, Cipla Inc., Dr. Reddy's Laboratories, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Glenmark Pharmaceuticals, Hikma Pharmaceuticals PLC, Ipca Laboratories Ltd., Lincoln Pharmaceuticals, Lupin Limited, Merck KGaA, Mylan, Novartis AG, Pfizer Inc., Sanofi Group, Strides Pharma Science Limited, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company, Teva Pharmaceuticals Industries Ltd., Zydus Group, and Zydus Lifesciences Ltd..

Market Segmentation & Coverage

This research report categorizes the Antimalarial Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Antifolate compounds, Artemisinin compounds, Aryl aminoalcohol compounds, Endoperoxides, Quinoline Methanols, and Tetracyclines.
• Based on Drug Type, market is studied across Branded and Generic.
• Based on Route of Administration, market is studied across Intravenous and Oral.
• Based on Malaria Type, market is studied across Plasmodium Falciparum, Plasmodium Knowlesi, Plasmodium Malariae, Plasmodium Ovale, and Plasmodium Vivax.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on End User, market is studied across Hospitals and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence rates of malaria globally, particularly in tropical and subtropical regions
    • 5.1.1.2. Increasing support from global health organizations for malaria eradication programs
  • 5.1.2. Restraints
    • 5.1.2.1. Emergence of drug-resistant malaria strains
  • 5.1.3. Opportunities
    • 5.1.3.1. Collaborations between governments and pharmaceutical companies for increasing penetration of anti-malaria drugs
    • 5.1.3.2. Research and development in drug development and diagnostic tests for malaria
  • 5.1.4. Challenges
    • 5.1.4.1. Issues related to incorrect dosing, strict compliance, and poor drug quality
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Class: Widening use of artemisinin compounds owing to its effective results
  • 5.2.2. Malaria Type: Increasing prevalence of plasmodium falciparum
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antimalarial Drugs Market, by Drug Class

• 6.1. Introduction
• 6.2. Antifolate compounds
• 6.3. Artemisinin compounds
• 6.4. Aryl aminoalcohol compounds
• 6.5. Endoperoxides
• 6.6. Quinoline Methanols
• 6.7. Tetracyclines

7. Antimalarial Drugs Market, by Drug Type

• 7.1. Introduction
• 7.2. Branded
• 7.3. Generic

8. Antimalarial Drugs Market, by Route of Administration

• 8.1. Introduction
• 8.2. Intravenous
• 8.3. Oral

9. Antimalarial Drugs Market, by Malaria Type

• 9.1. Introduction
• 9.2. Plasmodium Falciparum
• 9.3. Plasmodium Knowlesi
• 9.4. Plasmodium Malariae
• 9.5. Plasmodium Ovale
• 9.6. Plasmodium Vivax

10. Antimalarial Drugs Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Antimalarial Drugs Market, by End User

• 11.1. Introduction
• 11.2. Hospitals
• 11.3. Specialty Clinics

12. Americas Antimalarial Drugs Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Antimalarial Drugs Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Antimalarial Drugs Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2023
• 15.2. FPNV Positioning Matrix, 2023
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Kenya Manufacturer Is First In Africa to Get WHO Approval For Malaria Drug
  • 15.3.2. Fosun Pharma and IFC Partner to Improve Access to High Quality Medicines in Africa
  • 15.3.3. Fosun Pharma Develops Innovative Artemisinin-based Antimalarial Drugs
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Alkem Laboratories
• 3. Alliance Pharma
• 4. Alvizia Health Care
• 5. Bayer AG
• 6. Cipla Inc.
• 7. Dr. Reddy's Laboratories
• 8. F. Hoffmann-La Roche Ltd.
• 9. GlaxoSmithKline plc
• 10. Glenmark Pharmaceuticals
• 11. Hikma Pharmaceuticals PLC
• 12. Ipca Laboratories Ltd.
• 13. Lincoln Pharmaceuticals
• 14. Lupin Limited
• 15. Merck KGaA
• 16. Mylan
• 17. Novartis AG
• 18. Pfizer Inc.
• 19. Sanofi Group
• 20. Strides Pharma Science Limited
• 21. Sun Pharmaceutical Industries Ltd.
• 22. Takeda Pharmaceutical Company
• 23. Teva Pharmaceuticals Industries Ltd.
• 24. Zydus Group
• 25. Zydus Lifesciences Ltd.